{"name":"Intra-Cellular Therapies, Inc.","slug":"intra-cellular-therapies-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ITI-007 (Lumateperone)","genericName":"ITI-007 (Lumateperone)","slug":"iti-007-lumateperone","indication":"Schizophrenia (acute and maintenance treatment)","status":"phase_3"},{"name":"Lumateperone (ITI-007)","genericName":"Lumateperone (ITI-007)","slug":"lumateperone-iti-007","indication":"Schizophrenia","status":"phase_3"},{"name":"Lumateperone high dose","genericName":"Lumateperone high dose","slug":"lumateperone-high-dose","indication":"Schizophrenia (phase 3)","status":"phase_3"},{"name":"Lumateperone low dose","genericName":"Lumateperone low dose","slug":"lumateperone-low-dose","indication":"Schizophrenia","status":"phase_3"}]}],"pipeline":[{"name":"ITI-007 (Lumateperone)","genericName":"ITI-007 (Lumateperone)","slug":"iti-007-lumateperone","phase":"phase_3","mechanism":"Lumateperone is a serotonin 5-HT7 receptor antagonist and phosphodiesterase 1 inhibitor that modulates intracellular signaling pathways implicated in psychosis and mood disorders.","indications":["Schizophrenia (acute and maintenance treatment)","Bipolar disorder (in development)"],"catalyst":""},{"name":"Lumateperone (ITI-007)","genericName":"Lumateperone (ITI-007)","slug":"lumateperone-iti-007","phase":"phase_3","mechanism":"Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.","indications":["Schizophrenia","Bipolar depression"],"catalyst":""},{"name":"Lumateperone high dose","genericName":"Lumateperone high dose","slug":"lumateperone-high-dose","phase":"phase_3","mechanism":"Lumateperone is a serotonin 5-HT7 receptor antagonist and phosphodiesterase 10 (PDE10) inhibitor that modulates dopamine and glutamate signaling in the brain.","indications":["Schizophrenia (phase 3)","Bipolar depression (phase 3)"],"catalyst":""},{"name":"Lumateperone low dose","genericName":"Lumateperone low dose","slug":"lumateperone-low-dose","phase":"phase_3","mechanism":"Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.","indications":["Schizophrenia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPUzdQOUVXR3BqVFdQcktSTXlXZldKbUY3MGRHTUpvaGFIZ3pSQ3FYcmo5bFhtbGI1cVVSbjhkdHhtbnpVbnN1ZTVNTHZHb1JEQVhSQ1JsdzlObFJ3QnBWX1p5WTRmTWRvR2VqUHBlZ0NWU0JqZWlwY0FoOHItNFhHZDBCQkVvQmNJSzBvTEZFRlhMR3FISUZ3UHVTbHpKYVNydzNVbjNiQmdTNGJYRWZYdWRxS3BIRk0xZmVCM1JhUQ?oc=5","date":"2026-03-25","type":"deal","source":"AD HOC NEWS","summary":"Intra-Cellular Therapies stock in spotlight amid Johnson & Johnson $14.6 billion acquisition deal re - AD HOC NEWS","headline":"Intra-Cellular Therapies stock in spotlight amid Johnson & Johnson $14.6 billion acquisition deal re","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBrbFY5MjJEV015dFlNOUhfUlVocG9WVmdZOThJTE5oLU0wX3lFUjdhckFMelItb05jV3JGeTBhUmlsYWE2LWZCWk5kbmF0T29BemEwZ3M3UjRxU0NWVmRsaDdvWnFOeWtKMHhoUTRWbWw1NnpT?oc=5","date":"2026-01-12","type":"deal","source":"Fierce Pharma","summary":"The top 10 biopharma M&A deals of 2025 - Fierce Pharma","headline":"The top 10 biopharma M&A deals of 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNUUtvSmJVazdLanpzd2gydUxGc2xseUIzZXB2d1ZhaFFNQjBWa0xaVTFTYVRHbWNzYzluVU5SMmFVUlBuUXNyR0JPSzZxWjY0cHp5NkZERVRzX1BrRkJuS3FkTmgwRFc5LXpPTTJTZm11b08xQTFZTXZXZ09xNGQwU1dsY3dBMHBIeHVB?oc=5","date":"2025-12-31","type":"pipeline","source":"Pharmaceutical Executive","summary":"JP Morgan 2026 Preview: Johnson & Johnson Prepares a Fireside Chat - Pharmaceutical Executive","headline":"JP Morgan 2026 Preview: Johnson & Johnson Prepares a Fireside Chat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOanBRUFRxMWVnZjBnTUU2c3JDMFZUdjVkcFNBYmJfY2hXX1VxMVFYR3h6MDFHUmNsU3otRXdic3hPSE5QelY3dEYxVDRWQndmRGx4UzBhcnozQmRONVp2VTAzYUdUM084T19qNTFWenhkTFgtZmFyeDY2Y005YzluVE9WeFVHY1dmV21VOFhlSTZDRk9UYXhHTnlPckliVHcyclFSa0RaVHNEaVowb1owR3FCYUdrNy1MczJSUDVOUWM?oc=5","date":"2025-12-12","type":"deal","source":"Pharmaceutical Technology","summary":"Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify - Pharmaceutical Technology","headline":"Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQaGhqWDAyY2tLbEhXRmlZZGp2ZjlIMjJmTWJ1QnE5QkhDZUtfZ0hYZXpnQmk3ajJhX0pnd0JEMXBKQklPcEpiODI4cFVmdkFodlBiX29VYXlPclJwM2tQZ1ZtLVdIalQydGQwSU5xTjRLbUpNdEdhM0FjdEMxOFhJcXhWZ1k4c3d2REREcjlJb083QTlYWXZyYkxzelYtYWZLYS1kY09feWpQY3Vjbi1F?oc=5","date":"2025-11-19","type":"pipeline","source":"BioSpace","summary":"Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions - BioSpace","headline":"Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOMUJRRExsM005ZEFOZTZJNk04RU5WOGlfSVhaYUlLOHo1U0VwNTFBekpHTTE5QzRaTXZkQk5jWE8xakZfNzRWTHZIYnhVSmJfdmloVUVSb0phbG5VOWlzdkJWYmFVVFpUUnlaQXJSd2MzcHZuWWhoUC1vb1BhUW5wZ3dHTlA0WGZmeTlZNG9DLVE4anVhRFM1REI3SVV1Z0lBRVBaUXVyR05WNnFnVTQ1RGtCMmY?oc=5","date":"2025-11-06","type":"regulatory","source":"Fierce Pharma","summary":"J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder - Fierce Pharma","headline":"J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9EMzNyMDhRbjh1VHlqUWRGRURwLXA0bTFvdDM2Tk9YVDZfeDh2aFE3MUNCSFFRYXo0MWI1VW1VSUdISkRlQXMxcDRfbjJBZ0o5R1N2dFJTMktTOXVlaEVFQTlBbi1rcGxyUENEZjRkVjNiN21WNFF2ejZjc3g?oc=5","date":"2025-10-30","type":"pipeline","source":"DCAT Value Chain Insights","summary":"Emerging Pharma: On the Industry’s Radar - DCAT Value Chain Insights","headline":"Emerging Pharma: On the Industry’s Radar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQNmNjMzMxUl9OWHV0UEFOb3lva1dQRm5HZVFQUm5CeDJObXR5M0FNeElrY3Z3S2RIcEFQSlg5SG8xbTd3b3hEOXZHTkZhajN4QWFrYXdDTTh2UmNsUEpVUUhEUG5RcnQxaTdmUG5qeTA1a0xXSHAzNDA0VWJqUkFlb3NJX25EaWxiQjNpT0JMMlhUT2EzamExRA?oc=5","date":"2025-01-13","type":"deal","source":"reuters.com","summary":"J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal - reuters.com","headline":"J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQZi0wOFlVd3V0YzhmTVZmRnIyQ2ZJNDltWUJJYUlpZWVfMWNLQjhETkRIUVdwdFV1YXJTUlI2aGo1ZWxKS1lBZTVZNmp5RkNmVnBNeG1mdmVYc1RqRlA2N0ZsNFR5TjVUZzJIa2M4Z21nUjdWb3BQYnJvX1pDQUVqVTMyeWE1d09nMmhjZTk2ellKOFlCeTdfcTJLUGU3RmFMVWNZ?oc=5","date":"2025-01-13","type":"deal","source":"statnews.com","summary":"J&J to buy Intra-Cellular Therapies for $14.6B, picking up mental health drug - statnews.com","headline":"J&J to buy Intra-Cellular Therapies for $14.6B, picking up mental health drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQc0IxLUl0TWtQU0drMXAyelBnTENwUlNGT3NyUTJteWxNcUM3d0tlVHRlUFZEZWlmSjNaOW9EQlFjSHJDeTdxSEowN1ByWjdzM3gyY3NKblhYYXpsaDNRNlVrQlAzVDlGYzl6S08zdGxqWlgtc2k2VlgtRWp0aWVYSERRRU96TS01M1ZlWHNhUURQTk5lU3ppVURuZDRNVkxvc3h4SUlCaw?oc=5","date":"2025-01-13","type":"deal","source":"Contract Pharma","summary":"Johnson & Johnson Agrees to Acquire Intra-Cellular Therapies - Contract Pharma","headline":"Johnson & Johnson Agrees to Acquire Intra-Cellular Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeHFnYTZmalFVVEFqejNCQWNGTENKcUx5SDBLQkxlZXlTUWxLRlpPRXRRREVJZ1htRlBaUDZEcU05Y2k2TmtveXR6VS1nTUhZRU5vU3pOSm91Q0hXU0dPV3lKdTBoMnBKWV8yWE16cTUxMWhEaldMU3RCYmd4WVFVWldId3F4WlU1a1A2eWRfelRsZ3pPU2FwOFdka1NySFpkN2M5b01lYVE?oc=5","date":"2025-01-13","type":"deal","source":"WSJ","summary":"Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal - WSJ","headline":"Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNbmJMc2tnOFVOZUs3Q1E4UjNBU29Uc0J4LWxnUzlCZXpNWmY2MWVnNUx3aU9hdVlUZ2FGSDVjSGJ0V3RDdHJGNGlsb2I4c3J5dFI4dDU5S09CM3M5a1lIeEVIc1hRUk0yQ3kweEVRcGlKTmRoRFZZajdiOWJVY2ZGRkRRV0RTS3A0VDBta04wNzlKTzhDSVN1MWpsYTEwT0hMRE5VRXl0bzE5WkQ3?oc=5","date":"2025-01-13","type":"deal","source":"BioPharma Dive","summary":"J&J to buy psychiatric drug developer Intra-Cellular for $14.6B - BioPharma Dive","headline":"J&J to buy psychiatric drug developer Intra-Cellular for $14.6B","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}